# US 8,278,262 B2 · Use of microproteins as tryptase inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,262 B2
- Document ID: US8278262B2
- Status: Granted
- Kind: B2
- Application number: 11/663,435
- Filed: 2005-09-19
- Published: 2009-05-21
- Granted: 2012-10-02
- Earliest claimed: 2004-09-21
- Assignees: BioNTech SE
- Inventors: Harald Kolmar; Christian Sommerhoff; Alexander Wentzel
- Web page: https://patentgrep.com/patent/US8278262B2

## CPC

- A61K 38/56: from plants
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 19/00: Drugs for skeletal disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07K 14/47: from mammals
- C30B 7/00: Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions (from molten solvents C30B9/00; by normal or gradient freezing C30B11/00; under a protective fluid C30B27/00)
- C30B 29/58: Macromolecular compounds
- C07K 2319/00: Fusion polypeptide
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C30B: SINGLE-CRYSTAL GROWTH (by using ultra-high pressure, e.g. for the formation of diamonds, B01J3/06); UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL (zone-refining of metals or alloys C22B); PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (casting of metals, casting of other substances by the same processes or devices B22D; working of plastics B29; modifying the physical structure of metals or alloys C21D, C22F); SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE (for producing semiconductor devices or parts thereof H10); APPARATUS THEREFOR

## Abstract

Disclosed are uses of microproteins preferably microproteins forming a cystine knot (i.e. belonging to the family of inhibitor cystine knot (ICK) polypeptides) or polynucleotides encoding said microproteins for the preparation of a pharmaceutical composition for treating or preventing a disease that can be treated or prevented by inhibiting the activity of tryptase as well as corresponding methods of treatment. Also disclosed are uses of the microproteins for inhibiting tryptase activity, for purifying tryptase, as a carrier molecule for tryptase and for deleting or quantifying tryptase in a sample, including corresponding diagnostic applications. Furthermore disclosed are fusion proteins comprising an inactive barnase as well as fusion proteins comprising barnase and a microprotein. Also encompassed are nucleic acid molecules encoding such a fusion protein, as well as corresponding vectors, host cells, preparation methods and uses of the fusion protein. Moreover, the present application discloses a crystal of a microprotein fused with barnase, preferably inactive barnase. The disclosure also refers to corresponding preparation methods for the crystal, structure analysis methods using the crystal data storage media comprising the structure data obtained, as well as to in silico methods using the structure data for characterizing the binding of microproteins to target molecules. Furthermore, disclosed are pharmaceutical compositions comprising the crystal and corresponding medical uses.

## Claims

### Claim 1

A method for treating or preventing-asthma that can be treated or prevented by inhibiting the activity of tryptase comprising administering to a subject in need thereof an isolated microprotein, wherein the microprotein comprises an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17.

### Claim 2 (depends on 1)

The method of claim 1, wherein the microprotein comprises at least six cysteine residues, of which six cysteine residues are connected via disulphide bonds so as to form a cystine knot.

### Claim 3 (depends on 1)

The method of claim 1, wherein the microprotein has a peptide backbone with an open or a circular conformation.

### Claim 4 (depends on 1)

The method of claim 1, wherein the microprotein is fused to barnase.

### Claim 5 (depends on 4)

The method of claim 4, wherein the barnase is inactive.

### Claim 6 (depends on 1)

The method of claim 1, wherein the microprotein is administered to the patient in the form of a gene delivery vector which expresses the microprotein.

### Claim 7 (depends on 6)

The method of claim 6, wherein the cells are transformed with the vector ex vivo and the transformed cells are administered to the patient.

### Claim 8 (depends on 1)

A method for the treatment of an individual with asthma comprising administering to said individual an effective amount of a pharmaceutical composition comprising the microprotein as defined in claim 1 and, optionally, a pharmaceutically acceptable carrier.

### Claim 9

A method of diagnosing asthma related to an aberrant expression of tryptase, wherein the method comprises:
contacting a sample from a cell, tissue, organ or organism with a microprotein, wherein the microprotein comprises an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17;
determining the amount of the microprotein bound to tryptase;
comparing the determined amount bound to tryptase to a standard amount; and
diagnosing asthma.

### Claim 10

A kit comprising an isolated microprotein and a manual for carrying out a method of diagnosing asthma related to an aberrant expression of tryptase and, means of detection or a standard tryptase sample; wherein the microprotein consists of an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17.

### Claim 11

A method for treating or preventing asthma comprising administering to a subject a fusion protein comprising barnase and a microprotein, wherein the microprotein comprises an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17.

### Claim 12 (depends on 11)

The method of claim 11, wherein said barnase is inactive.

### Claim 13 (depends on 11)

A method of treating or preventing asthma of claim 11, wherein the fusion protein is administered to the patient as a gene delivery vector comprising a nucleic acid molecule, wherein the nucleic acid molecule comprises a nucleotide sequence encoding the fusion protein of claim 11.

### Claim 14 (depends on 13)

The method of claim 13, wherein the nucleic acid molecule comprises DNA, cDNA, or RNA.

### Claim 15 (depends on 13)

The method of claim 13, wherein the nucleotide sequence encoding the fusion protein is operably linked to one or more expression control sequences allowing the expression of the fusion protein in a host cell.

### Claim 16 (depends on 13)

The method of claim 13, wherein the subject is administered a host cell genetically engineered with the vector comprising said nucleic acid molecule.

### Claim 17 (depends on 16)

A method for preparing a fusion protein comprising cultivating the host cell of claim 16 under conditions that the fusion protein encoded by said nucleic acid molecule or vector is expressed; and recovering the fusion protein from the culture.

### Claim 18 (depends on 17)

The method of claim 17, wherein said recovering comprises a step in which the fusion protein is purified by way of binding the barnase moiety of the fusion protein to barstar.

### Claim 19

A method of treating or preventing asthma comprising administering to a subject in need thereof a crystal of a microprotein fused with barnase, wherein the microprotein comprises an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17.

### Claim 20 (depends on 19)

The method of claim 19, wherein the microprotein comprises the amino acid sequence depicted in SEQ ID NO: 7.

### Claim 21 (depends on 19)

The method of claim 19, wherein the barnase is inactive.

### Claim 22 (depends on 19)

The method of claim 19 wherein the microprotein fused with barnase comprises the amino acid sequence set forth in SEQ ID NO: 19.

### Claim 23 (depends on 19)

The method of claim 19, wherein the crystal belongs to space group C2221.

### Claim 24 (depends on 19)

The method of claim 19, wherein the crystal has the unit cell dimensions of a=73.981 Å, b=217.820 Å and c=58.322 Å, α=β=γ=90°.

### Claim 25 (depends on 19)

The method of claim 19 wherein the crystal has the crystal coordinates as depicted in Table 6.

### Claim 26 (depends on 19)

The method of claim 19, wherein a pharmaceutical composition comprises the crystal and, optionally, a pharmaceutically acceptable carrier.

### Claim 27

A method for preventing asthma that can be prevented by inhibiting the activity of tryptase comprising administering to a subject in need thereof an isolated microprotein, wherein the microprotein consists of an amino acid sequence selected from the group consisting of:
the amino acid sequence depicted in anyone of SEQ ID NOs: 1 to 17.

### Claim 28 (depends on 27)

The method of claim 27, wherein the microprotein is fused to barnase.

### Claim 29 (depends on 28)

The method of claim 28, wherein the barnase is inactive.

### Claim 30 (depends on 27)

The method of claim 27, wherein the microprotein is administered to the patient in the form of a gene delivery vector which expresses the microprotein.

### Claim 31 (depends on 29)

The method of claim 29, wherein the cells are transformed with the vector ex vivo and the transformed cells are administered to the patient.
